<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Nonstress test and contraction stress test
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Nonstress test and contraction stress test
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Nonstress test and contraction stress test
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David A Miller, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal health is evaluated, in part, by assessment of fetal heart rate patterns. The primary goal of antepartum fetal surveillance (antepartum testing) with the nonstress test (NST) and the contraction stress test (CST) is to identify fetuses at risk of hypoxic injury or death and intervene to prevent these adverse outcomes, if possible. The secondary goal is to identify normally oxygenated fetuses so that pregnancy can be continued safely, and unnecessary intervention can be avoided.
        </p>
        <p>
         An abnormal test (nonreactive NST, positive CST) is sometimes associated with adverse fetal or neonatal outcomes, while a normal test (reactive NST, negative CST) is usually associated with a neurologically intact and adequately oxygenated fetus. When interpreting these tests, the clinician needs to account for gestational age, results of prior fetal assessment, maternal conditions (including medications), and fetal condition (eg, growth restriction, anemia, arrhythmia).
        </p>
        <p>
         The NST and CST will be reviewed here. Intrapartum fetal evaluation and additional techniques for assessing fetal health are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/418.html" rel="external">
          "Intrapartum fetal heart rate monitoring: Overview"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5392.html" rel="external">
          "Biophysical profile test for antepartum fetal assessment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/444.html" rel="external">
          "Decreased fetal movement: Diagnosis, evaluation, and management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/459.html" rel="external">
          "Doppler ultrasound of the umbilical artery for fetal surveillance in singleton pregnancies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PHYSIOLOGIC BASIS OF FETAL HEART RATE CHANGES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physiologic development of the fetal heart occurs across gestation and affects fetal heart rate (FHR) patterns. Changes in FHR result from moment-to-moment autonomic modulation in response to many factors, including input from chemoreceptors, input from baroreceptors, central nervous system activities (eg, arousal, sleep), catecholamines, and blood volume [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Effect of gestational age on fetal heart rate
         </span>
         <span class="headingEndMark">
          —
         </span>
         The parasympathetic and sympathetic nervous systems exert a progressively greater influence on the FHR as gestational age advances. Parasympathetic innervation of the heart is mediated primarily by the vagus nerve, which influences the sinoatrial (SA) and atrioventricular (AV) nodes. Parasympathetic stimulation slows the FHR, and blockade by parasympatholytic medications (eg,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ) increases FHR [
         <a href="#rid2">
          2
         </a>
         ]. Sympathetic stimulation of the heart increases the FHR, and blockade of sympathetic activity slows the FHR.
        </p>
        <p>
         With advancing gestational age, the maturation of the parasympathetic system causes slowing of the baseline heart rate but usually not below the normal range of 110 to 160 beats per minute  (
         <a class="graphic graphic_figure graphicRef62797" href="/z/d/graphic/62797.html" rel="external">
          figure 1
         </a>
         ). Maturation of the sympathetic system causes an increase in the frequency and amplitude of FHR accelerations [
         <a href="#rid3">
          3,4
         </a>
         ]. For example, 50 percent of normal fetuses demonstrated accelerations with fetal movements at 24 weeks, while over 95 percent demonstrated accelerations at 30 weeks of gestation, in one study [
         <a href="#rid5">
          5
         </a>
         ]. Before 32 weeks, accelerations may increase by only 10 beats per minute above the baseline and last 10 seconds, whereas later in gestation, accelerations of 15 beats per minute above the baseline and lasting 15 seconds are expected [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Cardiovascular response to hypoxemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal oxygenation depends upon the adequate transfer of oxygen from the environment to the fetal tissues. Oxygen is transferred from the environment to fetal tissues by maternal and fetal blood along a pathway that includes the maternal lungs, heart, vasculature, and uterus and the fetal placenta and umbilical cord. Fetal hypoxemia (usually expressed as the partial pressure of oxygen dissolved in blood, or PO
         <sub>
          2
         </sub>
         ) can result from interruption of the transfer of oxygen from the environment to fetal tissue at any point along this pathway.
        </p>
        <p>
         The FHR response to interrupted oxygenation depends on the cause:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient fetal hypoxemia associated with uterine contractions can cause late decelerations. Stimulation of chemoreceptors in the fetal carotid arteries and aortic arch leads to a reflex increase in sympathetic outflow, causing vasoconstriction in nonvital peripheral areas and preservation of, or increases in, blood flow to vital organs (eg, adrenal glands, heart, brain). Peripheral vasoconstriction causes elevated fetal blood pressure and, in turn, stimulation of baroreceptors in the fetal carotid arteries and aortic arch, resulting in reflex, vagally mediated, parasympathetic slowing of FHR shortly after the beginning of the contraction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient interruption of fetal oxygenation caused by compression of the umbilical cord can result in variable decelerations. If cord compression reduces blood flow in the umbilical vein first, transient hypovolemia may cause a reflex rise in FHR (sometimes referred to as a "shoulder"). Subsequent arterial compression increases blood pressure, leading to vagally mediated slowing of FHR until the cord compression resolves.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute ongoing interruption of fetal oxygenation at the level of the maternal lungs (eg, maternal hypoxemia), maternal heart (eg, acute reduction in cardiac output), maternal vasculature (eg, maternal hypotension), uterus (eg, tetanic contraction, uterine rupture), placenta (eg, abruption), or umbilical cord (eg, prolapse) can cause prolonged decelerations.
        </p>
        <p>
        </p>
        <p>
         By comparison, early decelerations are not caused by fetal hypoxemia and not associated with adverse outcome. They are caused by fetal head compression, which increases intracranial pressure, resulting in reflex slowing of the FHR. Available evidence does not support fetal extracranial pressure exerted by uterine contractions as a cause of fetal brain injury [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2460604427">
         <span class="h1">
          EQUIPMENT AND NOMENCLATURE
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Equipment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Electronic fetal monitors are used to continuously record the fetal heart rate (FHR) in graphical form. In most external FHR monitoring systems, the FHR is measured by focusing an ultrasound beam on the fetal heart from a small Doppler ultrasound device placed on the maternal abdomen. A bedside monitor interprets the Doppler signals, which reflect cardiac motion. The complex wave generated is analyzed, and the peak is used for calculations. An internal computer then calculates the FHR by averaging several consecutive peak-to-peak frequencies to minimize artifact. This process of averaging is called "autocorrelation." It produces a FHR waveform closely resembling that derived from a fetal electrocardiogram (ECG).
        </p>
        <p>
         A recent generation of fetal monitors calculates FHR, FHR variability, and fetal QT intervals from information obtained from multiple electrodes placed on the maternal abdomen (eg, Monica AN24 monitor, MindChild Medical monitor). The maternal ECG signal and ambient noise are filtered out by algorithms run by microprocessors. This software provides noninvasive fetal ECGs that are purported to be as accurate as the information obtained from a fetal scalp electrode [
         <a href="#rid8">
          8-10
         </a>
         ]. It is useful in patients with obesity in whom continuous Doppler ultrasound monitoring is technically difficult and does not provide an adequate quality FHR tracing for interpretation.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Nomenclature
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most commonly used American system for describing FHR findings was developed by a workshop convened by the National Institute of Child Health and Human Development  (
         <a class="graphic graphic_table graphicRef65859" href="/z/d/graphic/65859.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          OVERVIEW OF ANTEPARTUM FETAL HEART RATE TESTING
         </span>
        </p>
        <p class="headingAnchor" id="H1050269004">
         <span class="h2">
          Background
         </span>
         <span class="headingEndMark">
          —
         </span>
         The NST and CST are used for antepartum fetal heart rate (FHR) testing. Although one study reported a lower incidence of fetal death among high-risk pregnancies undergoing antepartum testing (with NST and amniotic fluid index [AFI]) compared with low-risk untested pregnancies, there remains no conclusive evidence from randomized trials that use of NSTs and CSTs leads to a reduction in fetal death or neurologic injury [
         <a href="#rid12">
          12
         </a>
         ]. Nevertheless, performing NSTs or CSTs in pregnancies deemed to be at high risk of adverse fetal outcome is a standard obstetric practice in the United States and elsewhere, based on circumstantial evidence and long-standing convention. (See
         <a class="local">
          'Test performance'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2532738684">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary goal of antepartum testing is to reduce the risk of stillbirth by identifying fetuses at risk for hypoxic injury or death [
         <a href="#rid13">
          13
         </a>
         ]. A secondary goal is to identify normally oxygenated fetuses so that expectant management of high-risk pregnancies can be continued safely. Thus, antepartum FHR testing is performed in pregnancies considered to be at increased risk of fetal hypoxic injury or demise. Examples include pregnancies that are complicated by maternal conditions associated with placental dysfunction or poor uteroplacental perfusion. Some fetal disorders are also associated with an increased risk of fetal hypoxic injury or death. (See
         <a class="medical medical_review" href="/z/d/html/457.html" rel="external">
          "Overview of antepartum fetal assessment", section on 'Indications for fetal assessment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2460605322">
         <span class="h2">
          Test performance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of the NST and CST became widespread in the early 1980s when a seminal observational study reported stillbirth rates (corrected for lethal congenital anomalies and unpredictable causes of demise) after reactive and nonreactive NSTs were 1.9 and 26 per 1000 births, respectively [
         <a href="#rid14">
          14
         </a>
         ]. The stillbirth rates after a negative CST, reactive positive CST, or nonreactive positive CST were 0.3, 0, and 88 per 1000 births, respectively. These findings supported use of these tests to identify fetuses who might benefit from early delivery.
        </p>
        <p>
         In 2015, a Cochrane review attempted to determine whether using the NST can improve maternal or perinatal outcome by identifying high-risk pregnancies requiring prompt induction of labor or immediate delivery by cesarean [
         <a href="#rid15">
          15
         </a>
         ]. Six randomized trials involving 2105 participants were included. Tested patients were compared with controls who did not undergo NSTs or their test results were concealed. No significant differences between groups were noted in maternal outcomes, such as frequency of induction of labor or cesarean birth, or in infant outcomes, including perinatal mortality, low five-minute Apgar, neonatal intensive care unit admission, and neonatal seizures. Perinatal mortality (adjusted for lethal anomalies) in the testing group was higher than in controls (2.3 versus 1.1 percent, four studies, n = 1627, odds ratio 2.05, 95% CI 0.95-4.42). By contrast, when the authors compared computerized cardiotocography (automated evaluation of the FHR) versus traditional cardiotocography, computerized cardiotocography was associated with a statistically significant reduction in perinatal mortality (relative risk [RR] 0.20, 95% CI 0.04-0.88, two trials, 0.9 versus 4.2 percent, n = 469). There was no statistically significant difference in potentially preventable deaths (RR 0.23, 95% CI 0.04-1.29, two trials, n = 469); however, the meta-analysis was underpowered to assess this outcome.
        </p>
        <p>
         There are many limitations to the trials in this meta-analysis, which preclude definitive assessment of the value of the NST in current practice. Randomization methods were suboptimal, which could have created bias. The total number of adverse events, such as perinatal mortality and abnormal neurologic signs, was too low to determine whether small, but statistically significant, differences in outcome might result from testing. Furthermore, the trials were conducted in the early 1980s when these tests were first introduced into clinical practice and clinicians were inexperienced in test interpretation and subsequent pregnancy management. It is possible that the tests would be interpreted and acted upon differently today with different outcomes. Lastly, fetal assessment and neonatal care have changed since the 1980s; the combined use of ultrasound and FHR testing may be more predictive of fetal status and need for intervention than either test alone.
        </p>
        <p class="headingAnchor" id="H2460605265">
         <span class="h2">
          Choice of test
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no evidence from randomized trials on which to base a recommendation for use of the CST versus the NST for antepartum fetal monitoring. Although some observational studies suggest that the CST is more predictive of adverse outcome than the NST [
         <a href="#rid14">
          14,16
         </a>
         ], others have not demonstrated any improvement in predicting perinatal morbidity compared with the NST, even when both tests are combined [
         <a href="#rid17">
          17
         </a>
         ]. The only randomized trial comparing antepartum fetal testing methods was inconclusive [
         <a href="#rid18">
          18
         </a>
         ]. This trial compared the biophysical profile (BPP; which includes an NST) with the NST alone in management of 652 high-risk pregnancies. Costs were not considered.
        </p>
        <p>
         However, the CST is less convenient to perform than the NST since it requires either an intravenous line for infusion of a dilute
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         solution or nipple stimulation, and it tends to be more time consuming. It also has some relative contraindications. (See
         <a class="local">
          'Overview'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3355433605">
         <span class="h2">
          Timing and frequency
         </span>
         <span class="headingEndMark">
          —
         </span>
         NSTs and CSTs are initiated at the gestational age that the fetus is believed to be at increased risk of death as long as the age is sufficiently advanced that delivery for perinatal benefit would be considered. For the NST, fetal neurologic maturity should be sufficient to enable FHR acceleration (typically no earlier than 26 to 28 weeks).
        </p>
        <p>
         There is no high-quality evidence defining the optimal frequency of testing [
         <a href="#rid19">
          19
         </a>
         ]. Reported test frequencies include weekly NST, weekly CST with midweek NST, twice weekly NST with once weekly AFI, and twice weekly NST with twice weekly AFI [
         <a href="#rid20">
          20
         </a>
         ]. Testing is performed periodically as long as the indication for testing persists, but maternal or fetal deterioration requires reevaluation despite recent normal test results [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Maternal or fetal deterioration requires reevaluation despite recent normal test results. Although a pattern of accelerations, moderate variability, and no significant decelerations during the NST and CST reliably identifies the absence of ongoing hypoxic injury during the test, it does not preclude such injury in the future, especially if there are significant changes in the clinical setting over time.
        </p>
        <p class="headingAnchor" id="H2532735539">
         <span class="h2">
          Management of pregnancies with normal or abnormal test results
         </span>
         <span class="headingEndMark">
          —
         </span>
         An abnormal test result is generally followed by additional testing with a different test, given the high rate of false-positive results. The clinical setting also needs to be considered. If a temporary maternal condition may account for the abnormal test result, prompt treatment of the maternal condition may also improve fetal oxygenation and lead to a normal test result on subsequent testing. In chronic conditions, clinical judgment guides management and needs to consider case-specific factors. (See
         <a class="medical medical_review" href="/z/d/html/457.html" rel="external">
          "Overview of antepartum fetal assessment", section on 'Follow-up of pregnancies with normal test results'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/457.html" rel="external">
          "Overview of antepartum fetal assessment", section on 'Management of pregnancies with abnormal test results'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          NONSTRESS TEST
         </span>
        </p>
        <p class="headingAnchor" id="H131906679">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         The NST is the most common cardiotocographic method of antepartum fetal assessment. It is noninvasive and can be performed in any setting where an electronic fetal monitor is available. There is no direct risk of maternal or fetal injury associated with NSTs.
        </p>
        <p>
         The NST may be performed with or without sonographic assessment of amniotic fluid volume. When using amniotic fluid volume assessment, the deepest vertical pocket of fluid, rather than the amniotic fluid index (AFI), may be associated with fewer unnecessary interventions without an increase in adverse perinatal outcomes [
         <a href="#rid13">
          13
         </a>
         ]; however, not all experts agree and further study is warranted [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/457.html" rel="external">
          "Overview of antepartum fetal assessment", section on 'Biophysical profile and modified biophysical profile'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23600030">
         <span class="h2">
          Reactive tests
         </span>
        </p>
        <p class="headingAnchor" id="H1401256932">
         <span class="h3">
          Criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         The NST is reactive from 32 weeks to term if there are two or more fetal heart rate (FHR) accelerations reaching a peak of at least 15 beats per minute (bpm) above the baseline rate and lasting at least 15 seconds from onset to return to baseline (15 x 15) in a 20-minute period  (
         <a class="graphic graphic_figure graphicRef72845" href="/z/d/graphic/72845.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_table graphicRef65859" href="/z/d/graphic/65859.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid6">
          6,13,22
         </a>
         ]. A reactive test provides reliable evidence of normal fetal oxygenation, regardless of the length of observation time needed to demonstrate reactivity [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2495755770">
         <span class="h4">
          Before 32 weeks of gestation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Different criteria have been suggested for gestational ages less than 32 weeks (see
         <a class="local">
          'Effect of gestational age on fetal heart rate'
         </a>
         above). Before 32 weeks of gestation, a reactive NST may be defined as two accelerations that rise at least 10 bpm above baseline and have a duration of at least 10 seconds (10 x 10) [
         <a href="#rid11">
          11,13
         </a>
         ]. Whether clinicians choose to apply the conventional 15 x 15 criteria or adopt the 10 x 10 criteria when performing NSTs before 32 weeks of gestation, they should use the same approach in all patients. However, once a fetus has demonstrated the maturity to generate accelerations of 15 bpm for 15 seconds, an acceleration of 10 bpm for 10 seconds may not have the same ability to confirm normal fetal oxygenation, even before 32 weeks of gestation. Available evidence has not resolved this issue definitively.
        </p>
        <p>
         The validity of the 10 x 10 criteria before 32 weeks was based on the following two studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study of 143 participants who underwent antepartum testing before 32 weeks, the frequency of adverse perinatal outcomes was similar when 10 x 10 criteria were used to define a normal test rather than the conventional 15 x 15 criteria, and the time required to achieve a reactive NST was shorter with the less stringent criteria [
         <a href="#rid24">
          24
         </a>
         ]. However, the study was not powered to detect differences in adverse outcome or to confirm the safety of applying the 10 x 10 criteria before 32 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study including 488 subjects undergoing antepartum testing before 32 weeks, perinatal outcome was similar whether the last NST before delivery was reactive using 10 x 10 or 15 x 15 criteria [
         <a href="#rid25">
          25
         </a>
         ]. However, after controlling for known confounding factors, such as gestational age and birth weight, there was a trend toward more perinatal deaths following a reactive 10 x 10 NST than following a reactive 15 x 15 NST.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2056038963">
         <span class="h3">
          Minimal duration of FHR monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of the NST has not been established. Some sources recommend the NST should be continued for at least 20 minutes, even if two qualifying accelerations have been observed before that time [
         <a href="#rid26">
          26
         </a>
         ]. However, large studies evaluating the predictive value of the NST combined with amniotic fluid volume assessment have not included this requirement [
         <a href="#rid12">
          12,27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H23600276">
         <span class="h3">
          Reactive NSTs with decelerations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The significance of a reactive NST with FHR decelerations is unclear. Multiple observational studies have described an increased frequency of intrapartum FHR decelerations and operative delivery when this combination occurs [
         <a href="#rid29">
          29-34
         </a>
         ], except when the decelerations are brief [
         <a href="#rid35">
          35
         </a>
         ]; however, outcomes are usually good. The majority of FHR decelerations during the NST are variable decelerations, reflecting transient episodes of umbilical cord compression.
        </p>
        <p>
         Variable, late, or prolonged decelerations observed during antepartum testing require further evaluation, which might include extended FHR and uterine activity monitoring, ultrasound assessment of fetal growth and anatomy, BPP, amniotic fluid volume, and/or Doppler velocimetry in the setting of fetal growth restriction. Management decisions should be guided by the results of the additional evaluation and other details specific to the clinical situation. (See
         <a class="medical medical_review" href="/z/d/html/459.html" rel="external">
          "Doppler ultrasound of the umbilical artery for fetal surveillance in singleton pregnancies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139556.html" rel="external">
          "Fetal growth restriction: Pregnancy management and outcome", section on 'Fetal surveillance'
         </a>
         .)
        </p>
        <p>
         Intermittent fetal cardiac arrhythmias can also cause decelerations and may be diagnosed by echocardiography. Management depends on the arrhythmia and patient-specific factors. (See
         <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">
          "Fetal arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23600037">
         <span class="h2">
          Nonreactive tests
         </span>
        </p>
        <p class="headingAnchor" id="H3136663160">
         <span class="h3">
          Criteria and causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         A NST is nonreactive if it does not meet acceleration criteria for a reactive NST (see
         <a class="local">
          'Reactive tests'
         </a>
         above). The FHR should be monitored for at least 40 minutes before interpreting the test as nonreactive.
        </p>
        <p>
         Nonreactivity may be a sign of interrupted fetal oxygenation to the point of metabolic acidemia. The mean umbilical vein pH associated with a nonreactive NST is 7.28±0.11, which is higher than the pH associated with a low biophysical profile (BPP) score, 7.16±0.08 [
         <a href="#rid36">
          36
         </a>
         ]. (The normal range of antepartum fetal umbilical vein pH established by cordocentesis is shown in the table  (
         <a class="graphic graphic_table graphicRef76880" href="/z/d/graphic/76880.html" rel="external">
          table 2
         </a>
         ).)
        </p>
        <p>
         Other possible causes of a nonreactive NST include fetal immaturity, fetal sleep, maternal smoking, fetal neurologic or cardiac anomalies, sepsis, or maternal ingestion of drugs with cardiac effects [
         <a href="#rid37">
          37
         </a>
         ]. Sleep is a common and benign cause of a nonreactive NST. Sleep cycles may last up to 40 minutes [
         <a href="#rid5">
          5
         </a>
         ]; one study reported sleep cycles lasting up to 53 minutes [
         <a href="#rid38">
          38
         </a>
         ]. In a study that observed late preterm fetuses from uncomplicated pregnancies for 100 minutes, quiet sleep occurred at least once in 30 percent of fetuses, but 96 percent of the fetuses cycled between quiet sleep and active states during the period of observation [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1536151250">
         <span class="h3">
          Evaluation of pregnancies with nonreactive NSTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to 60 percent of nonreactive NSTs may be false positives, usually defined as a nonreactive NST that prompts delivery, but delivery is not associated with findings suggestive of acute interruption of fetal oxygenation (eg, FHR decelerations or loss of variability, meconium passage, operative delivery for acute FHR changes, low Apgar scores, or abnormal umbilical cord blood gas values) or chronic suboptimal fetal oxygenation (eg, fetal growth restriction, oligohydramnios).
        </p>
        <p>
         A nonreactive NST usually warrants further evaluation. Some options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat the test in 30 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform vibroacoustic stimulation to elicit accelerations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform a back-up test, (either CST or complete BPP) [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5392.html" rel="external">
          "Biophysical profile test for antepartum fetal assessment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If possible, modify factors potentially causing nonreactive results (eg, smoking proximate to the test).
        </p>
        <p>
        </p>
        <p>
         Vibroacoustic stimulation can decrease the number of nonreactive NSTs and shorten test time without reducing the predictive value of a reactive NST. A vibroacoustic source, typically an artificial larynx, placed on or just above the maternal abdomen, is used to stimulate fetal movement. In a 2013 systematic review, vibroacoustic stimulation decreased mean overall testing time by almost seven minutes, compared with mock or no stimulation (-6.93, 95% CI -12.09 to -1.76), and reduced the frequency of nonreactive NSTs by 40 percent (odds ratio 0.62, 95% CI 0.48-0.81) [
         <a href="#rid40">
          40
         </a>
         ]. There are no evidence-based standards for performing this procedure. It has been performed as soon as five minutes after initiation of the NST. The stimulus is applied for one to five seconds and may be repeated. The optimal placement and number of applications of the stimulus have not been evaluated. The American College of Obstetricians and Gynecologists suggests positioning the device on the maternal abdomen and applying a stimulus for one to two seconds [
         <a href="#rid13">
          13
         </a>
         ]. If no fetal response occurs, the stimulus may be repeated up to three times for progressively longer durations of up to three seconds.
        </p>
        <p>
         Transabdominal light stimulation with a halogen light for 10 seconds appears to stimulate the fetus and may be as effective as vibroacoustic stimulation [
         <a href="#rid41">
          41-43
         </a>
         ]. More safety and efficacy data are needed before this method can be recommended in place of vibroacoustic stimulation. One study found that fetal exposure to recorded music was associated with increased fetal movement, increased number of accelerations, and improved variability [
         <a href="#rid44">
          44
         </a>
         ]. Musical intervention may be a noninvasive and inexpensive tool for shortening the time to reactivity.
        </p>
        <p>
         Although commonly practiced, neither maternal glucose administration nor transabdominal manual fetal manipulation significantly decreases the incidence of nonreactive test results [
         <a href="#rid45">
          45,46
         </a>
         ].
        </p>
        <p>
         Changing maternal position does not increase reactivity as long as the patient is tested in a position that does not lead to hypotension from uterine compression of the great vessels [
         <a href="#rid47">
          47
         </a>
         ]. Cocoa and caffeine consumption may affect fetal movement, but the dose, timing, and effect on NST reactivity have not been evaluated [
         <a href="#rid48">
          48-50
         </a>
         ]. No randomized trials or observational studies have assessed the effect of maternal hydration (oral or intravenous) on FHR reactivity. Maternal hydration (oral or intravenous) may increase the AFI [
         <a href="#rid51">
          51-53
         </a>
         ] and decrease the baseline FHR [
         <a href="#rid54">
          54,55
         </a>
         ], but there is no evidence that it increases fetal movement or heart rate reactivity.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          CONTRACTION STRESS TEST
         </span>
        </p>
        <p class="headingAnchor" id="H503480633">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CST is not used as often as the NST because it is less convenient to perform (see
         <a class="local">
          'Choice of test'
         </a>
         above). It is also more limited by contraindications than the NST. Relative contraindications to stimulating contractions for a CST are conditions that are also contraindications to labor and vaginal birth, such as placenta previa, vasa previa, and previous classical cesarean birth or extensive uterine surgery. Preterm labor, patients at high risk for preterm birth, and preterm prelabor rupture of membranes are also relative contraindications.
        </p>
        <p class="headingAnchor" id="H368508961">
         <span class="h2">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the CST, either a dilute
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         solution is infused or nipple stimulation is performed until three contractions occur within 10 minutes. There is no standard technique for nipple stimulation. Patients gently massage the nipple of one breast through their clothes for two minutes, stopping with onset of contractions; stimulation is resumed if contractions are too infrequent for CST interpretation. Both nipples can be stimulated if no contractions occur. In patients who are having spontaneous contractions of adequate frequency, oxytocin or nipple stimulation is unnecessary.
        </p>
        <p class="headingAnchor" id="H680014371">
         <span class="h3">
          Interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The CST is interpreted as follows [
         <a href="#rid13">
          13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive
         </strong>
         – A positive (abnormal) test has late decelerations following ≥50 percent of contractions. The test is positive even if the contraction frequency is less than three in 10 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Negative
         </strong>
         – A negative (normal) test has no late decelerations or significant variable decelerations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Equivocal
         </strong>
         – An equivocal-suspicious test has intermittent late decelerations or significant variable decelerations, while an equivocal-tachysystolic has decelerations with contractions occurring more frequently than every two minutes or lasting longer than 90 seconds.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unsatisfactory
         </strong>
         – An unsatisfactory test has fewer than three contractions in 10 minutes (and is not positive as defined above), or is uninterpretable for other reasons.
        </p>
        <p>
        </p>
        <p>
         The presence or absence of accelerations is also generally noted. For example, a reactive positive CST meets criteria for both a reactive NST and a positive CST.
        </p>
        <p>
         The American College of Obstetricians and Gynecologists has not defined what they intended by the term "significant" variable decelerations. No data are available on which to base a recommendation for the definition of "significant variable" in the context of antepartum testing. The NICHD chose not to grade the severity of intrapartum variable decelerations based on the depth of the deceleration, absolute nadir, or duration [
         <a href="#rid11">
          11
         </a>
         ]. However, one expert group defined significant variables during labor as those that include either of the following characteristics: lasting &gt;60 seconds and reaching a nadir &gt;60 bpm below baseline or lasting &gt;60 seconds and reaching a nadir &lt;60 bpm (regardless of baseline) [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2460605166">
         <span class="h3">
          Evaluation of pregnancies with positive CSTs
         </span>
         <span class="headingEndMark">
          —
         </span>
         A positive (abnormal) CST indicates transient fetal hypoxemia during uterine contractions and may be an indication for delivery, depending on the clinical scenario. Further evaluation might include a biophysical profile (BPP) and, in the setting of fetal growth restriction, Doppler velocimetry. A CST with variable decelerations suggests umbilical cord compression that may be due to oligohydramnios [
         <a href="#rid29">
          29
         </a>
         ]. Management of pregnancies complicated by oligohydramnios is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6777.html" rel="external">
          "Oligohydramnios: Etiology, diagnosis, and management in singleton gestations"
         </a>
         .)
        </p>
        <p>
         In one study, 50 percent of reactive positive CSTs were false positives, whereas 100 percent of nonreactive positive CSTs were true positives [
         <a href="#rid57">
          57
         </a>
         ]. Thus, the presence of accelerations during the CST may reduce the need for intervention, but additional evaluation (eg, BPP) is warranted [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3746665868">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/126123.html" rel="external">
          "Society guideline links: Fetal surveillance"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antenatal fetal surveillance
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications
         </strong>
         – Antepartum fetal surveillance (antepartum testing) with the nonstress test (NST) or the contraction stress test (CST) is performed in pregnancies considered to be at increased risk for fetal hypoxic injury or demise. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Goals
         </strong>
         – The primary goal of antepartum testing is to reduce the risk of stillbirth by identifying fetuses at risk for hypoxic injury or death so that appropriate intervention (eg, measures directed at improving fetal oxygenation, delivery) might be undertaken to prevent these adverse outcomes, if possible. The secondary goal is to identify normally oxygenated fetuses so that pregnancy can be continued safely, and unnecessary intervention can be avoided. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Physiology
         </strong>
         – Changes in the fetal heart rate (FHR) reflect the fetal response to input from chemoreceptors, baroreceptors, central nervous system activities, hormonal regulation, and blood volume. Gestational age is a factor in interpretation of FHR patterns. (See
         <a class="local">
          'Physiologic basis of fetal heart rate changes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Timing and frequency
         </strong>
         – NSTs and CSTs are initiated at the gestational age that the fetus is believed to be at increased risk of death as long as the age is sufficiently advanced that delivery for perinatal benefit would be considered. The frequency of testing depends upon maternal and fetal status and is usually performed once or twice weekly as long as the indication for testing persists. Maternal or fetal deterioration requires reevaluation despite recent normal test results. (See
         <a class="local">
          'Timing and frequency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Choice of test
         </strong>
         – The NST (with or without amniotic fluid assessment) has become the preferred antepartum test of fetal oxygenation status because the CST, which usually requires stimulation of uterine contractions, is more time-consuming, more invasive, and more limited by contraindications than the NST. The biophysical profile (BPP) is a reasonable alternative. (See
         <a class="local">
          'Choice of test'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Abnormal testing
         </strong>
         – An abnormal test result is generally followed by additional testing with a different test, given the high rate of false-positive results. (See
         <a class="local">
          'Management of pregnancies with normal or abnormal test results'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonstress test
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥32 weeks of gestation
         </strong>
         – The NST is considered reactive if there are two or more FHR accelerations reaching a peak of at least 15 beats per minute (bpm) above the baseline rate and lasting at least 15 seconds from onset to return to baseline in a 20-minute period  (
         <a class="graphic graphic_figure graphicRef72845" href="/z/d/graphic/72845.html" rel="external">
          figure 2
         </a>
         ). There are no published data to confirm a benefit of extending the duration of NST once two qualifying accelerations have been observed. A reactive test reliably predicts normal fetal oxygenation at the time of testing. (See
         <a class="local">
          'Reactive tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          &lt;32 weeks of gestation
         </strong>
         – Before 32 weeks, a reactive NST can be defined by at least two accelerations of at least 10 bpm lasting for at least 10 seconds and over a 20-minute interval. Once a fetus has demonstrated the maturity to have accelerations of 15 bpm for 15 seconds, an acceleration of 10 bpm for 10 seconds may no longer be sufficient to confirm normal fetal oxygenation, even if less than 32 weeks of gestation. (See
         <a class="local">
          'Reactive tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nonreactive
         </strong>
         –The FHR should be monitored for at least 40 minutes before interpreting the test as nonreactive. Abnormal test results may be due to interruption of fetal oxygenation but should be interpreted within the context of the clinical situation. Vibroacoustic stimulation is useful for decreasing the number of nonreactive NSTs and for shortening test time. (See
         <a class="local">
          'Nonreactive tests'
         </a>
         above and
         <a class="local">
          'Evaluation of pregnancies with nonreactive NSTs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reactive with decelerations
         </strong>
         – Variable, late, or prolonged decelerations observed during a NST require further evaluation  (
         <a class="graphic graphic_table graphicRef65859" href="/z/d/graphic/65859.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Reactive NSTs with decelerations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraction stress test
         </strong>
         – The CST is interpreted as follows (see
         <a class="local">
          'Contraction stress test'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Positive
         </strong>
         – Late decelerations following ≥50 percent of contractions, even if the contraction frequency is less than three in 10 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Negative
         </strong>
         – No late decelerations or significant variable decelerations with contraction frequency of three in 10 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Equivocal
         </strong>
         – Intermittent late decelerations or significant variable decelerations, while an equivocal-tachysystolic has decelerations with contractions occurring more frequently than every two minutes or lasting longer than 90 seconds.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Unsatisfactory
         </strong>
         – Uninterpretable or fewer than three contractions in 10 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Reactive positive CSTs are often false positives, whereas nonreactive positive CSTs are generally true positives. Thus, the presence of accelerations during the CST may reduce the need for intervention, but additional evaluation (eg, BPP) is warranted. (See
         <a class="local">
          'Evaluation of pregnancies with positive CSTs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         <strong>
          ACKNOWLEDGMENT
         </strong>
         — The UpToDate editorial staff acknowledges Bruce K Young, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Parer JT. Fetal heart rate. In: Maternal Fetal Medicine: Principles and Practice, Creasy, Resnik (Eds), WB Saunders Company, Philadelphia 1999.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abboud T, Raya J, Sadri S, et al. Fetal and maternal cardiovascular effects of atropine and glycopyrrolate. Anesth Analg 1983; 62:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadovsky G, Nicolaides KH. Reference ranges for fetal heart rate patterns in normoxaemic nonanaemic fetuses. Fetal Ther 1989; 4:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park MI, Hwang JH, Cha KJ, et al. Computerized analysis of fetal heart rate parameters by gestational age. Int J Gynaecol Obstet 2001; 74:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillai M, James D. The development of fetal heart rate patterns during normal pregnancy. Obstet Gynecol 1990; 76:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop. Am J Obstet Gynecol 1997; 177:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyborne KD. A Systematic Review of Intrapartum Fetal Head Compression: What Is the Impact on the Fetal Brain? AJP Rep 2017; 7:e79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clifford G, Sameni R, Ward J, et al. Clinically accurate fetal ECG parameters acquired from maternal abdominal sensors. Am J Obstet Gynecol 2011; 205:47.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen WR, Ommani S, Hassan S, et al. Accuracy and reliability of fetal heart rate monitoring using maternal abdominal surface electrodes. Acta Obstet Gynecol Scand 2012; 91:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhard J, Hayes-Gill BR, Schiermeier S, et al. Intrapartum signal quality with external fetal heart rate monitoring: a two way trial of external Doppler CTG ultrasound and the abdominal fetal electrocardiogram. Arch Gynecol Obstet 2012; 286:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macones GA, Hankins GD, Spong CY, et al. The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines. Obstet Gynecol 2008; 112:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller DA, Rabello YA, Paul RH. The modified biophysical profile: antepartum testing in the 1990s. Am J Obstet Gynecol 1996; 174:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antepartum Fetal Surveillance: ACOG Practice Bulletin, Number 229. Obstet Gynecol 2021; 137:e116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. I. Risk of perinatal mortality and morbidity according to antepartum fetal heart rate test results. Am J Obstet Gynecol 1982; 143:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grivell RM, Alfirevic Z, Gyte GM, Devane D. Antenatal cardiotocography for fetal assessment. Cochrane Database Syst Rev 2015; :CD007863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman RK, Anderson G, Dorchester W. A prospective multi-institutional study of antepartum fetal heart rate monitoring. II. Contraction stress test versus nonstress test for primary surveillance. Am J Obstet Gynecol 1982; 143:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olofsson P, Sjöberg NO, Solum T. Fetal surveillance in diabetic pregnancy. II. The nonstress test versus the oxytocin challenge test. Acta Obstet Gynecol Scand 1986; 65:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Platt LD, Walla CA, Paul RH, et al. A prospective trial of the fetal biophysical profile versus the nonstress test in the management of high-risk pregnancies. Am J Obstet Gynecol 1985; 153:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rouse DJ, Owen J, Goldenberg RL, Cliver SP. Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision-analytic approach. Am J Obstet Gynecol 1995; 173:1357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Signore C, Freeman RK, Spong CY. Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop. Obstet Gynecol 2009; 113:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wax JR, Pinette MG. The amniotic fluid index and oligohydramnios: a deeper dive into the shallow end. Am J Obstet Gynecol 2022; 227:462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evertson LR, Gauthier RJ, Schifrin BS, Paul RH. Antepartum fetal heart rate testing. I. Evolution of the nonstress test. Am J Obstet Gynecol 1979; 133:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown R, Patrick J. The nonstress test: how long is enough? Am J Obstet Gynecol 1981; 141:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cousins LM, Poeltler DM, Faron S, et al. Nonstress testing at ≤ 32.0 weeks' gestation: a randomized trial comparing different assessment criteria. Am J Obstet Gynecol 2012; 207:311.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glantz JC, Bertoia N. Preterm nonstress testing: 10-beat compared with 15-beat criteria. Obstet Gynecol 2011; 118:87.
          </a>
         </li>
         <li class="breakAll">
          American Academy Of Pediatrics, American College of Obstetricians and Gynecologists. Guidelines for Perinatal Care, 8th, 2017. p.201.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nageotte MP, Towers CV, Asrat T, et al. The value of a negative antepartum test: contraction stress test and modified biophysical profile. Obstet Gynecol 1994; 84:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nageotte MP, Towers CV, Asrat T, Freeman RK. Perinatal outcome with the modified biophysical profile. Am J Obstet Gynecol 1994; 170:1672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoskins IA, Frieden FJ, Young BK. Variable decelerations in reactive nonstress tests with decreased amniotic fluid index predict fetal compromise. Am J Obstet Gynecol 1991; 165:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Begum F, Buckshee K. Foetal compromise by spontaneous foetal heart rate deceleration in reactive non-stress test and decreased amniotic fluid index. Bangladesh Med Res Counc Bull 1998; 24:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glantz C, D'Amico ML. Lack of relationship between variable decelerations during reactive nonstress tests and oligohydramnios. Am J Perinatol 2001; 18:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judge NE, Mann LI, Lupe P, Amini S. Clinical associations of variable decelerations during reactive nonstress tests. Obstet Gynecol 1989; 74:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelan JP, Lewis PE Jr. Fetal heart rate decelerations during a nonstress test. Obstet Gynecol 1981; 57:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce SL, Petrie RH, Davison J. Prediction of abnormal umbilical cord position and intrapartum cord problems from the nonstress test. Diagn Gynecol Obstet 1980; 2:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meis PJ, Ureda JR, Swain M, et al. Variable decelerations during nonstress tests are not a sign of fetal compromise. Am J Obstet Gynecol 1986; 154:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manning FA, Snijders R, Harman CR, et al. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. Am J Obstet Gynecol 1993; 169:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oncken C, Kranzler H, O'Malley P, et al. The effect of cigarette smoking on fetal heart rate characteristics. Obstet Gynecol 2002; 99:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suwanrath C, Suntharasaj T. Sleep-wake cycles in normal fetuses. Arch Gynecol Obstet 2010; 281:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillai M, James D. Behavioural states in normal mature human fetuses. Arch Dis Child 1990; 65:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan KH, Smyth RM, Wei X. Fetal vibroacoustic stimulation for facilitation of tests of fetal wellbeing. Cochrane Database Syst Rev 2013; :CD002963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caridi BJ, Bolnick JM, Fletcher BG, Rayburn WF. Effect of halogen light stimulation on nonstress testing. Am J Obstet Gynecol 2004; 190:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolnick JM, Garcia G, Fletcher BG, Rayburn WF. Cross-over trial of fetal heart rate response to halogen light and vibroacoustic stimulation. J Matern Fetal Neonatal Med 2006; 19:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahimikian F, Rahiminia T, Modarres M, Mehran A. Comparison of halogen light and vibroacoustic stimulation on nonreactive fetal heart rate pattern. Iran J Nurs Midwifery Res 2013; 18:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gebuza G, Dombrowska A, Kaźmierczak M, et al. The effect of music therapy on the cardiac activity parameters of a fetus in a cardiotocographic examination. J Matern Fetal Neonatal Med 2017; 30:2440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan KH, Sabapathy A. Maternal glucose administration for facilitating tests of fetal wellbeing. Cochrane Database Syst Rev 2012; :CD003397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan KH, Sabapathy A, Wei X. Fetal manipulation for facilitating tests of fetal wellbeing. Cochrane Database Syst Rev 2013; :CD003396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moffatt FW, van den Hof M. Semi-Fowler's positioning, lateral tilts, and their effects on nonstress tests. J Obstet Gynecol Neonatal Nurs 1997; 26:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devoe LD, Murray C, Youssif A, Arnaud M. Maternal caffeine consumption and fetal behavior in normal third-trimester pregnancy. Am J Obstet Gynecol 1993; 168:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulder EJ, Tegaldo L, Bruschettini P, Visser GH. Foetal response to maternal coffee intake: role of habitual versus non-habitual caffeine consumption. J Psychopharmacol 2010; 24:1641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buscicchio G, Lorenzi S, Tranquilli AL. The effects of different concentrations of cocoa in the chocolate intaken by the mother on fetal heart rate. J Matern Fetal Neonatal Med 2013; 26:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilpatrick SJ, Safford KL, Pomeroy T, et al. Maternal hydration increases amniotic fluid index. Obstet Gynecol 1991; 78:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilpatrick SJ, Safford KL. Maternal hydration increases amniotic fluid index in women with normal amniotic fluid. Obstet Gynecol 1993; 81:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magann EF, Doherty DA, Chauhan SP, et al. Effect of maternal hydration on amniotic fluid volume. Obstet Gynecol 2003; 101:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oosterhof H, Haak MC, Aarnoudse JG. Acute maternal rehydration increases the urine production rate in the near-term human fetus. Am J Obstet Gynecol 2000; 183:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Powers DR, Brace RA. Fetal cardiovascular and fluid responses to maternal volume loading with lactated Ringer's or hypotonic solution. Am J Obstet Gynecol 1991; 165:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark SL, Nageotte MP, Garite TJ, et al. Intrapartum management of category II fetal heart rate tracings: towards standardization of care. Am J Obstet Gynecol 2013; 209:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braly P, Freeman RK. The significance of fetal heart rate reactivity with a positive oxytocin challenge test. Obstet Gynecol 1977; 50:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farahani G, Fenton AN. Fetal heart rate acceleration in relation to the oxytocin challenge test. Obstet Gynecol 1977; 49:163.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 409 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Parer JT. Fetal heart rate. In: Maternal Fetal Medicine: Principles and Practice, Creasy, Resnik (Eds), WB Saunders Company, Philadelphia 1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6829946" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Fetal and maternal cardiovascular effects of atropine and glycopyrrolate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2486889" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reference ranges for fetal heart rate patterns in normoxaemic nonanaemic fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11502295" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Computerized analysis of fetal heart rate parameters by gestational age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2216230" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The development of fetal heart rate patterns during normal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9423739" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Electronic fetal heart rate monitoring: research guidelines for interpretation. National Institute of Child Health and Human Development Research Planning Workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28465865" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A Systematic Review of Intrapartum Fetal Head Compression: What Is the Impact on the Fetal Brain?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514560" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinically accurate fetal ECG parameters acquired from maternal abdominal sensors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22924738" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Accuracy and reliability of fetal heart rate monitoring using maternal abdominal surface electrodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22714064" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Intrapartum signal quality with external fetal heart rate monitoring: a two way trial of external Doppler CTG ultrasound and the abdominal fetal electrocardiogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757666" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The 2008 National Institute of Child Health and Human Development workshop report on electronic fetal monitoring: update on definitions, interpretation, and research guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8633648" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The modified biophysical profile: antepartum testing in the 1990s.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34011889" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Antepartum Fetal Surveillance: ACOG Practice Bulletin, Number 229.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7102744" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A prospective multi-institutional study of antepartum fetal heart rate monitoring. I. Risk of perinatal mortality and morbidity according to antepartum fetal heart rate test results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26363287" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Antenatal cardiotocography for fetal assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7102745" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A prospective multi-institutional study of antepartum fetal heart rate monitoring. II. Contraction stress test versus nonstress test for primary surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3739648" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fetal surveillance in diabetic pregnancy. II. The nonstress test versus the oxytocin challenge test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4061530" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A prospective trial of the fetal biophysical profile versus the nonstress test in the management of high-risk pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7503167" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Determinants of the optimal time in gestation to initiate antenatal fetal testing: a decision-analytic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19300336" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35452652" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The amniotic fluid index and oligohydramnios: a deeper dive into the shallow end.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/760532" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Antepartum fetal heart rate testing. I. Evolution of the nonstress test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7315894" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The nonstress test: how long is enough?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021694" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Nonstress testing at≤32.0 weeks' gestation: a randomized trial comparing different assessment criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21691167" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Preterm nonstress testing: 10-beat compared with 15-beat criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21691167" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Preterm nonstress testing: 10-beat compared with 15-beat criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8041536" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The value of a negative antepartum test: contraction stress test and modified biophysical profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8203424" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Perinatal outcome with the modified biophysical profile.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1951521" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Variable decelerations in reactive nonstress tests with decreased amniotic fluid index predict fetal compromise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10874369" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Foetal compromise by spontaneous foetal heart rate deceleration in reactive non-stress test and decreased amniotic fluid index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11414522" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Lack of relationship between variable decelerations during reactive nonstress tests and oligohydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2668818" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clinical associations of variable decelerations during reactive nonstress tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7465129" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Fetal heart rate decelerations during a nonstress test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7472143" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prediction of abnormal umbilical cord position and intrapartum cord problems from the nonstress test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3953704" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Variable decelerations during nonstress tests are not a sign of fetal compromise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8238129" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11978283" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The effect of cigarette smoking on fetal heart rate characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19434415" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sleep-wake cycles in normal fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2306133" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Behavioural states in normal mature human fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24318543" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Fetal vibroacoustic stimulation for facilitation of tests of fetal wellbeing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15167872" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Effect of halogen light stimulation on nonstress testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16854694" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cross-over trial of fetal heart rate response to halogen light and vibroacoustic stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23983739" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Comparison of halogen light and vibroacoustic stimulation on nonreactive fetal heart rate pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27819173" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The effect of music therapy on the cardiac activity parameters of a fetus in a cardiotocographic examination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972062" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Maternal glucose administration for facilitating tests of fetal wellbeing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24318544" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Fetal manipulation for facilitating tests of fetal wellbeing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9313185" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Semi-Fowler's positioning, lateral tilts, and their effects on nonstress tests.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8475956" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Maternal caffeine consumption and fetal behavior in normal third-trimester pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19506007" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Foetal response to maternal coffee intake: role of habitual versus non-habitual caffeine consumption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23480746" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The effects of different concentrations of cocoa in the chocolate intaken by the mother on fetal heart rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1945215" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Maternal hydration increases amniotic fluid index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8416460" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Maternal hydration increases amniotic fluid index in women with normal amniotic fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12798534" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effect of maternal hydration on amniotic fluid volume.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10920336" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Acute maternal rehydration increases the urine production rate in the near-term human fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1835566" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Fetal cardiovascular and fluid responses to maternal volume loading with lactated Ringer's or hypotonic solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23628263" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Intrapartum management of category II fetal heart rate tracings: towards standardization of care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/927760" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : The significance of fetal heart rate reactivity with a positive oxytocin challenge test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/834397" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Fetal heart rate acceleration in relation to the oxytocin challenge test.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
